Condition: Influenza · Acute Respiratory Distress Syndrome · Sponsor: University Hospital, Bordeaux
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.
This description comes directly from the study's public registry record.
Renaud PREVEL, Dr · 5 57 87 26 26 · renaud.prevel@u-bordeaux.fr
Always discuss trial participation with your own doctor first.
| Hopital Pellegrin | Bordeaux, France | Recruiting |
| Hopital Haut-Lévêque | Pessac, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06254313